$Artelo Biosciences (ARTL.US)$
Revolutionary CBD Tablet Formulation Achieves Breakthrough Pharmacokinetic Results vs Epidiolex

$Artelo Biosciences (ARTL.US)$
Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12
Monday, 13th January at 9:00 am
The first selective Fatty Acid Binding Protein 5 inhibitor safely administered to human subjects
Initial safety and pharmacokinetic data expected during the first half 2025
SOLANA BEACH, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc (NASDAQ: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid...

$Artelo Biosciences (ARTL.US)$ Artelo Biosciences Presents Phase 1 Data On ART27.13 For Cancer-Related Anorexia At International Conference, Highlighting Good Tolerability And Weight Stabilization Or Reversal In Two-Thirds Of Participants; Phase 2 Enrollment Ongoing In CAReS Trial
Benzinga· 2 mins ago

$Artelo Biosciences (ARTL.US)$ 😜❤️

$Draganfly (DPRO.US)$ $Onfolio (ONFO.US)$ $Pulmatrix (PULM.US)$ $NFT Ltd (MI.US)$ $Artelo Biosciences (ARTL.US)$ $Streamline Health Solutions (STRM.US)$ $FOUNDER GROUP LIMITED (FGL.US)$ $Exicure (XCUR.US)$ $U.S. Goldmining (USGO.US)$ $Tokyo Lifestyle (TKLF.US)$ $AgEagle Aerial Systems (UAVS.US)$ $Sintx Technologies (SINT.US)$ $Gaucho Group (VINO.US)$ $Jowell Global (JWEL.US)$
📊⚡️📊

$Artelo Biosciences (ARTL.US)$
Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium
SOLANA BEACH, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, an...

$Artelo Biosciences (ARTL.US)$ SS’s are out in full force this morning!

$Artelo Biosciences (ARTL.US)$ Benzinga· 3 mins ago
Artelo Biosciences Receives FDA Clearance Of Its IND Application For ART26.12

$Artelo Biosciences (ARTL.US)$
Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor
Artelo Biosciences (Nasdaq: ARTL) has received FDA clearance for its Investigational New Drug (IND) application for ART26.12, a selective Fatty Acid Binding Protein 5 (FABP5) inhibitor. This clearance allows Artelo to initiate a Phase 1 single ascending dose study for chemotherapy-induced peripheral neuropathy (CIPN), a condition with...

$Artelo Biosciences (ARTL.US)$
Artelo Biosciences presented comparative preclinical data on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium. Findings revealed ART12.11, a novel cannabidiol: tetramethylpyrazine cocrystal, has a unique pharmacokinetic profile, potentially superior to existing...